Usefulness of Atypical Antipsychotics and Choline Esterase Inhibitors in Delirium: A Review

 

 Buy Article Permissions and Reprints

Abstract

Delirium is characterized by disturbances of consciousness, attention, cognition, perception, emotions, sleep, and psychomotor activity. Management of delirium involves ensuring safety, improving functioning, identifying and treating the illness underlying the delirium, and use of antipsychotics or benzodiazepines to control behavioural symptoms and prevent mortality. Haloperidol continues to be the most commonly used antipsychotic in delirium. However, in recent times data have emerged which suggest that atypical antipsychotics may be as efficacious as haloperidol in the treatment of delirium. This review intends to review the data with respect to usefulness of atypical antipsychotics in the treatment of delirium. Besides atypical antipsychotics, data with respect to another group of medications – cholinesterase inhibitors are also reviewed. Electronic and manual searches were conducted to identify all the relevant studies and case reports/case series. Evidence suggests that risperidone, olanzapine and quetiapine are as efficacious as haloperidol in the treatment of delirium but have lesser side effects. Data for other atypical antipsychotics are scarce. The data on cholinesterase inhibitors for treatment and prevention of delirium are beginning to accumulate, but do not seem to be convincing. Our review suggests that risperidone, olanzapine and quetiapine are good alternatives to haloperidol in the treatment of delirium.

References

• 1 American Psychiatric Association . Practice guideline for the treatment of patients with delirium.  Am J Psychiatry. 1999;  156 1-20
  PubMedGoogle Scholar
• 2 Lipowski ZJ. Delirium (acute confusional states).  JAMA. 1987;  258 1789-1792
  CrossrefPubMedGoogle Scholar
• 3 Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients.  Am J Psychiatry. 1983;  140 1048-1050
  PubMedGoogle Scholar
• 4 Cole MG, Primeau FJ. Prognosis of delirium in elderly hospital patients.  CMAJ. 1993;  149 41-46
  PubMedGoogle Scholar
• 5 Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients.  Ann Pharmacother. 2006;  40 1966-1973
  CrossrefPubMedGoogle Scholar
• 6 Sipahimalani A, Sime RM, Masand PS. Treatment of delirium with risperidone.  Int J Geriatr Psychopharmacol. 1997;  1 24-26
  PubMedGoogle Scholar
• 7 Liu CY, Juang YY, Liang HY. et al . Efficacy of risperidone in treating the hyperactive symptoms of delirium.  Int Clin Psychopharmacol. 2004;  19 165-168
  CrossrefPubMedGoogle Scholar
• 8 Gupta N, Sharma P, Mattoo SK. Effectiveness of risperidone in delirium.  Can J Psychiatry. 2005;  50 75
  PubMedGoogle Scholar
• 9 Miyaji S, Yamamoto K, Hoshino S. et al . Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients.  Psychiatry Clin Neurosci. 2007;  61 275-282
  CrossrefPubMedGoogle Scholar
• 10 Mittal D, Jimerson NA, Neely EP. et al . Risperidone in the treatment of delirium: Results from a prospective open-label trial.  J Clin Psychiatry. 2004;  65 662-667
  CrossrefPubMedGoogle Scholar
• 11 Horikawa N, Yamazaki T, Miyamoto K. et al . Treatment of delirium with risperidone: Results of a prospective open trial with 10 patients.  Gen Hosp Psychiatry. 2003;  25 289-292
  CrossrefPubMedGoogle Scholar
• 12 Parellada E, Baeza I, Pablo JD. et al . Risperidone in the treatment of patients with delirium.  J Clin Psychiatry. 2004;  65 348-353
  CrossrefPubMedGoogle Scholar
• 13 Toda H, Kusumi I, Sasaki Y. et al . Relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium.  Int Clin Psychopharmacol. 2005;  20 331-333
  CrossrefPubMedGoogle Scholar
• 14 Ikezawa K, Canuet L, Ishii R. et al . Efficacy of risperidone in the treatment of delirium in elderly patients.  Psychogeriatrics. 2008;  8 62-65
  CrossrefPubMedGoogle Scholar
• 15 Kim JY, Jung IK, Han C. et al . Antipsychotics and dopamine transporter gene polymorphisms in delirium patients.  Psychiatry Clin Neurosci. 2005;  59 183-188
  CrossrefPubMedGoogle Scholar
• 16 Han C, Kim Y. A double-blind trial of risperidone and haloperidol for the treatment of delirium.  Psychosomatics. 2004;  45 297-301
  CrossrefPubMedGoogle Scholar
• 17 Sipahimalani A, Masand PS. Use of risperidone in delirium: case reports.  Ann Clin Psychiatry. 1997;  9 105-107
  CrossrefPubMedGoogle Scholar
• 18 Bourgeois JA, Hilty DM. Prolonged delirium managed with risperidone.  Psychosomatics. 2005;  46 90-91
  CrossrefPubMedGoogle Scholar
• 19 Okumura K. Risperidone therapy for post-operative delirium in elderly patients.  Psychogeriatrics. 2005;  5 108-111
  CrossrefPubMedGoogle Scholar
• 20 Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium.  Psychosomatics. 1998;  39 422-429
  CrossrefPubMedGoogle Scholar
• 21 Kim K, Pae C, Chae J. et al . An open pilot trial of olanzapine for delirium in the Korean population.  Psychiatry Clin Neurosci. 2001;  55 515-519
  CrossrefPubMedGoogle Scholar
• 22 Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients.  Psychosomatics. 2002;  43 175-182
  CrossrefPubMedGoogle Scholar
• 23 Skrobik Y, Bergeron N, Dumont M. et al . Olanzapine vs. haloperidol: Treating delirium in a critical care setting.  Intens Care Med. 2004;  30 444-449
  CrossrefPubMedGoogle Scholar
• 24 Hu H, Deng W, Yang H. A prospective random control study comparison of olanzapine and haloperidol in senile delirium.  Chongging Med J. 2004;  8 1234-1237
  PubMedGoogle Scholar
• 25 Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine.  J Pain Symptom Manage. 1999;  17 219-223
  CrossrefPubMedGoogle Scholar
• 26 Lee Y, Lee J, Rim HD. et al . A comparative study of haloperidol and quetiapine in the treatment of delirium: a preliminary randomized open label, flexible dose trial.  Eur Neuropsychopharmacol. 2006;  16 (S 04) S488-S489
  PubMedGoogle Scholar
• 27 Maneeton B, Maneeton N, Srisurapanont M. An open-label study of quetiapine for delirium.  J Med Assoc Thai. 2007;  90 2158-2163
  PubMedGoogle Scholar
• 28 Shinno H, Matsuoka T, Yamamoto O. et al . Successful treatment with quetiapine for delirium in terminally ill cancer patients.  Psychogeriatrics. 2007;  7 64-68
  CrossrefPubMedGoogle Scholar
• 29 Omura K, Amano N. Clinical experience of quetiapine in 24 elderly patients with delirium.  Psychogeriatrics. 2003;  3 69-72
  CrossrefPubMedGoogle Scholar
• 30 Sasaki Y, Matsuyama T, Inoue S. et al . A prospective, open label, flexible-dose study of quetiapine in the treatment of delirium.  J Clin Psychiatry. 2003;  64 1316-1321
  CrossrefPubMedGoogle Scholar
• 31 Kim KY, Bader GM, Kotlyar V. et al . Treatment of delirium in older adults with quetiapine.  J Geriatr Psychiatry Neurol. 2003;  16 29-31
  CrossrefPubMedGoogle Scholar
• 32 Schwartz TL, Masand PS. Treatment of delirium with quetiapine. Primary Care Companion.  J Clin Psychiatry. 2000;  2 10-12
  PubMedGoogle Scholar
• 33 Lee KU, Won WY, Lee HK. et al . Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study.  Int Clin Psychopharmacol. 2005;  20 311-314
  CrossrefPubMedGoogle Scholar
• 34 Pae CU, Lee SJ, Lee CU. et al . A pilot trial of quetiapine for the treatment of patients with delirium.  Human Psychopharmacol. 2004;  19 125-127
  PubMedGoogle Scholar
• 35 Devlin JW, Roberts RJ, Fong JJ. et al . Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.  Crit Care Med. 2010;  38 419-427
  CrossrefPubMedGoogle Scholar
• 36 Torres R, Mittal D, Kennedy R. Use of quetiapine in delirium: case reports.  Psychosomatics. 2001;  42 347-349
  CrossrefPubMedGoogle Scholar
• 37 Al-Samarrai S, Dunn J, Newmark T. et al . Quetiapine for treatment-resistant delirium.  Psychosomatics. 2003;  44 350-351
  CrossrefPubMedGoogle Scholar
• 38 Kato D, Kawanishi C, Kishida I. et al . Delirium resolving upon switching from risperidone to quetiapine: implication of CYP2D6 genotype.  Psychosomatics. 2005;  46 374-375
  CrossrefPubMedGoogle Scholar
• 39 Seemüller F, Volkmer E, Vogel T. et al . Quetiapine as treatment for delirium during weaning from ventilation: a case report.  J Clin Psychopharmacol. 2007;  27 526-528
  CrossrefPubMedGoogle Scholar
• 40 Takeuchi T, Furuta K, Hirasawa T. et al . Perospirone in the treatment of patients with delirium.  Psychiatry Clin Neurosc. 2007;  61 67-70
  PubMedGoogle Scholar
• 41 Ushijima M, Yokoyama S, Sugiyama E. et al . Contribution of perospirone and risperidone to reduce delirium in senile patients.  Psychogeriatrics. 2008;  8 4-7
  CrossrefPubMedGoogle Scholar
• 42 Leso L, Schwartz TL. Ziprasidone treatment of delirium.  Psychosomatics. 2002;  43 61-62
  CrossrefPubMedGoogle Scholar
• 43 Young CC, Lujan E. Intravenous ziprasidone for treatment of delirium in the intensive care unit.  Anesthesiology. 2004;  101 794-795
  CrossrefPubMedGoogle Scholar
• 44 Girard TD, Pandharipande PP, Carson SS. et al . MIND Trial Investigators Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial.  Crit Care Med. 2010;  38 428-437
  CrossrefPubMedGoogle Scholar
• 45 Straker DA, Shapiro PA, Muskin PR. Aripiprazole in the treatment of delirium.  Psychosomatics. 2006;  47 385-391
  CrossrefPubMedGoogle Scholar
• 46 Tarumi Y, Watanabe S. The potential role of zuclopenthixol acetate in the management of refractory hyperactive delirium at the end of Life.  J Pain Symptom Manage. 2008;  35 336-339
  CrossrefPubMedGoogle Scholar
• 47 Wengel SP, Roccaforte WH, Burke WJ. Donepezil improves symptoms of delirium in dementia: implication for future research.  J Geriatr Psychiatry Neurol. 1998;  11 159-161
  PubMedGoogle Scholar
• 48 Wengel SP, Burke WJ, Roccaforte WH. Donepezil for postoperative delirium associated with Alzheimer's disease (letter).  J Am Geriatr Soc. 1999;  47 379-380
  PubMedGoogle Scholar
• 49 Kaufer DI, Catt KE, Lopez OL. et al . dementia with Lewy bodies: response of delirium-like features to donepezil.  Neurology. 1998;  51 1512
  PubMedGoogle Scholar
• 50 Hori K, Tominaga I, Inada T. et al . Donepezil-responsive alcohol-related prolonged delirium.  Psychiatry Clin Neurosci. 2003;  57 603-604
  CrossrefPubMedGoogle Scholar
• 51 Gleason OC. Donepezil for postoperative delirium.  Psychosomatics. 2003;  44 437-438
  CrossrefPubMedGoogle Scholar
• 52 Noyan MA, Elbi H, Aksu H. Donepezil for anticholinergic drug intoxication.  Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;  27 885-887
  CrossrefPubMedGoogle Scholar
• 53 Kobayashi K, Higashima M, Mutou K. et al . Severe delirium due to basal forebrain vascular lesion and efficacy of donepezil.  Progr Neuro-Psychopharmacol Biol Psychiatry. 2004;  28 1189-1194
  CrossrefPubMedGoogle Scholar
• 54 Logan CJ, Stewart JT. Treatment of post-electroconvulsive therapy delirium and agitation with donepezil.  J ECT. 2007;  23 28-29
  CrossrefPubMedGoogle Scholar
• 55 Liptzin B, Laki A, Garb JL. et al . Donepezil in the prevention and treatment of post-surgical delirium.  Am J Geriatr Psychiatry. 2005;  13 1100-1106
  CrossrefPubMedGoogle Scholar
• 56 Sampson EL, Raven PR, Ndhlovu PN. et al . A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement.  Int J Geriatr Psychiatry. 2007;  22 343-349
  CrossrefPubMedGoogle Scholar
• 57 Powers JS, Decoskey D, Kahrilas PJ. Physostigmine for treatment of delirium tremens.  J. Clin. Pharmacol. 1981;  21 57-60
  PubMedGoogle Scholar
• 58 Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase Inhibitors.  J Pain Sympt Manage. 2004;  27 268-273
  CrossrefPubMedGoogle Scholar
• 59 Goff DC, Garber HJ, Jenike MA. Partial resolution of ranitidine-associated delirium with physostigmine: case report.  J Clin Psychiatry. 1985;  46 400-401
  PubMedGoogle Scholar
• 60 Schuster P, Gabriel E, Küfferle B. et al . Reversal by physostigmine of clozapine-induced delirium.  Clin Toxicol. 1977;  10 437-441
  CrossrefPubMedGoogle Scholar
• 61 Stern TA. Continuous infusion of physostigmine in anticholinergic delirium: case report.  J Clin Psychiatry. 1983;  44 463-464
  PubMedGoogle Scholar
• 62 Blitt CD, Petty WC. Reversal of lorazepam delirium by physostigmine.  Anesth Analges. 1975;  54 607-608
  PubMedGoogle Scholar
• 63 Holinger PC, Klawans HL. Reversal of tricyclic-overdosage-induced central anticholinergic syndrome by physostigmine.  Am J Psychiatry. 1976;  133 1018-1023
  PubMedGoogle Scholar
• 64 Chapin JW, Wingard DW. Physostigmine reversal of benzquinamide-induced delirium.  Anesthesiology. 1977;  46 364-365
  CrossrefPubMedGoogle Scholar
• 65 Weizberg M, Su M, Mazzola JL. et al . Altered mental status from olanzapine overdose treated with physostigmine.  Clin Toxicol (Phila). 2006;  44 319-325
  CrossrefPubMedGoogle Scholar
• 66 Heiser JF, Wilbert DE. Reversal of delirium induced by tricyclic antidepressant drugs with physostigmine.  Am J Psychiatry. 1974;  131 1275-1277
  PubMedGoogle Scholar
• 67 Jost U, Schmid A, Ruppert M. [Physostigmine reversal of central anticholinergic syndrome induced by midazolam/fentanyl, benzoctamine/buprenorphine and etomidate/carticaine or by atropine/promethazine/pethidine for premedication? (author's transl)].  Anaesthesist. 1982;  31 21-24
  PubMedGoogle Scholar
• 68 Jenike MA, Levy JC. Physostigmine reversal of cimetidine-induced delirium and agitation.  J Clin Psychopharmacol. 1983;  3 43-44
  PubMedGoogle Scholar
• 69 Mendelson G. Reversal by physostigmine of delirium induced by ingestion of the flowers of the plant Datura stramonium.  Anesth Analges. 1976;  55 260
  PubMedGoogle Scholar
• 70 Funk W, Hollnberger H, Geroldinger J. Physostigmine and anaesthesia emergence delirium in preschool children: a randomized blind trial.  Eur J Anaesthesiol. 2008;  25 37-42
  CrossrefPubMedGoogle Scholar
• 71 Kalisvaart CJ, Boelaarts L, De Jonghe JFM. et al . Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine.  Ned Tijdschr Geneeskd. 2004;  148 1501-1504
  PubMedGoogle Scholar
• 72 Moretti R, Torre P, Antonello R. et al . Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients.  Am J Alzheimer's Dis Other Dementias. 2004;  19 333-339
  PubMedGoogle Scholar
• 73 Dautzenberg PL, Mulder LJ, Olde Rikkert MG. et al . Adding rivastigmine to antipsychotics in the treatment of a chronic delirium.  Age Ageing. 2004;  33 516-517
  CrossrefPubMedGoogle Scholar
• 74 Gamberini M, Bolliger D, Lurati Buse GA. et al . Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery – a randomized controlled trial.  Crit Care Med. 2009;  37 1762-1768
  Google Scholar
• 75 Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium.  Cochrane Database Syst Rev. 2007;  2 CD0055942
  PubMedGoogle Scholar

Correspondence

Dr. S. Grover

Department of Psychiatry

Postgraduate Institute of

Medical Education & Research

160012 Chandigarh

India

Phone: +91/172/275 6807

Fax: +91/172/274 4401

Fax: +91/172/274 5078

Email: drsandeepg2002@yahoo.com